News

SER-109 resulted in a 73% reduction in relative risk for CDI over 8 weeks.

Hospitalizations were more likely in patients with CDI of small bowel and Crohn's disease, with worse outcomes noted in patients admitted to ICU.

There is a substantial health care cost for CDI patients with sepsis.

In data presented at DDW, researchers find a decrease in hospital-acquired CDI infections in 2020 when compared to 2018 and 2019.

CX-01 added to standard of care was well-tolerated and did not increase incidence of bleeding in patients >59 years old.

In both studies, a higher proportion of patients on upadacitinib 15 mg and 30 mg achieved EASI-75, EASI-90, and EASI-100 compared with the placebo groups.

Veterans are particularly susceptible to opioid dependence and abuse.

Internet-delivered CBT may be an efficient and convenient means for addressing behaviors that exacerbate atopic dermatitis-related symptoms.

The researchers developed a computerized clinical decision support tool to help clinicians prescribe probiotics.

There was an association between exercise time and increased ejection fraction.

Patients treated with ruxolitnib cream show ≥75% improvement in facial vitiligo scoring index.

A daily opioid dose higher than 90 MME is associated with 3-fold risk increase, compared to 90 MME or lower.

A large proportion of HCV patients remain undiagnosed, particularly in the older population.

More and more individuals are becoming diagnosed with atrial fibrillation. But the research to halt this crisis is not quite there yet.

An expert discussion on climate change and air pollution effects on communities, including increased COVID-19 rates.

Vonoprazan has shown more potent acid inhibitory effects than PPI.

Early data suggests vaccines are effective against B.1.617.2 variant first discovered in India.

A survey at ACC 2021 showed 38% of cardiology professionals were burnt out during COVID-19. What factors in the field have already made it difficult to cope?

The high-risk patient population is under-represented in new research and agents. Why characteristics set it apart from other cardiovascular diseases?

Pegcetacoplan outperformed competitor in a phase 3 head-to-head study.

The anticoagulant did not improve clinical outcomes when compared with prophylactic anticoagulation.

Marc Bonaca, MD, explains the value of new assessments made in the pivotal peripheral artery disease clinical trial.

A cardiologist and wellness expert discusses new findings showing more than one-third of her peers were burnt out from experiences during the pandemic.

The Duke investigators return to discuss the pivotal study of rivaroxaban in peripheral artery disease.

There is no clear threshold for consumption leading to an AFib event.

Patients with a preserved ejection fraction saw a significant reduction in risk for cardiovascular-related adverse events and mortality.

Incidence rates decreased by nearly half after direct-acting antiviral treatment regimen.

A new analysis of the SCORED and SOLOIST trials suggests sotagliflozin could provide substantial benefit for reducing risk of cardiovascular death and worsening heart failure among patients with HFrEF and HFpEF.

New phase 2 data show the potential of the biologic in patients at risk of acute pancreatitis progression, but with a need for better variable understanding.

Investigators discuss recently-published secondary sex-based assessments into PCI treatment, as well as their contribution to cardiovascular research action points that lessen the field's disparities.